Ratios (Summary)

Celgene Corp., profitability ratios

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Return on Sales
Gross profit margin 96.45% 96.08% 95.41% 94.90% 94.65%
Operating profit margin 36.28% 28.31% 24.61% 33.30% 28.43%
Net profit margin 22.66% 17.87% 17.49% 26.44% 22.79%
Return on Investment
Return on equity (ROE) 42.48% 30.29% 27.07% 30.65% 25.94%
Return on assets (ROA) 9.75% 7.12% 5.92% 11.53% 10.84%

Source: Based on data from Celgene Corp. Annual Reports

Ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Celgene Corp.'s gross profit margin improved from 2015 to 2016 and from 2016 to 2017.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Celgene Corp.'s operating profit margin improved from 2015 to 2016 and from 2016 to 2017.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Celgene Corp.'s net profit margin improved from 2015 to 2016 and from 2016 to 2017.
ROE A profitability ratio calculated as net income divided by shareholders' equity. Celgene Corp.'s ROE improved from 2015 to 2016 and from 2016 to 2017.
ROA A profitability ratio calculated as net income divided by total assets. Celgene Corp.'s ROA improved from 2015 to 2016 and from 2016 to 2017.

Top


Gross Profit Margin

Celgene Corp., gross profit margin calculation

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Gross profit 12,512  10,747  8,741  7,178  6,022 
Net product sales 12,973  11,185  9,161  7,564  6,362 
Ratio
Gross profit margin1 96.45% 96.08% 95.41% 94.90% 94.65%
Benchmarks
Gross Profit Margin, Competitors
Abbott Laboratories 47.75% 54.09% 54.19% 51.73% 50.43%
AbbVie Inc. 75.05% 77.25% 80.31% 77.83% 75.62%
Allergan PLC 86.40% 87.23% 68.08% 51.74% 45.94%
Amgen Inc. 81.33% 80.99% 79.82% 77.12% 81.61%
Biogen Inc. 86.72% 87.08% 88.48% 87.93% 87.63%
Bristol-Myers Squibb Co. 70.80% 74.54% 76.39% 75.24% 71.81%
Eli Lilly & Co. 73.46% 73.35% 74.76% 74.85% 78.76%
Gilead Sciences Inc. 82.97% 85.77% 87.54% 84.52% 73.54%
Johnson & Johnson 66.84% 69.84% 69.27% 69.40% 68.67%
Merck & Co. Inc. 68.16% 65.10% 62.19% 60.30% 61.50%
Pfizer Inc. 78.61% 76.66% 80.25% 80.69% 81.42%
Regeneron Pharmaceuticals Inc. 93.24% 93.83% 90.43% 92.73% 92.62%

Source: Based on data from Celgene Corp. Annual Reports

2017 Calculations

1 Gross profit margin = 100 × Gross profit ÷ Net product sales
= 100 × 12,512 ÷ 12,973 = 96.45%

Ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Celgene Corp.'s gross profit margin improved from 2015 to 2016 and from 2016 to 2017.

Top


Operating Profit Margin

Celgene Corp., operating profit margin calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Operating income 4,707  3,167  2,255  2,519  1,809 
Net product sales 12,973  11,185  9,161  7,564  6,362 
Ratio
Operating profit margin1 36.28% 28.31% 24.61% 33.30% 28.43%
Benchmarks
Operating Profit Margin, Competitors
Abbott Laboratories 6.30% 15.27% 14.05% 12.84% 12.03%
AbbVie Inc. 33.99% 36.60% 32.97% 17.09% 30.14%
Allergan PLC -37.15% -12.53% -20.00% -9.71% -4.88%
Amgen Inc. 45.76% 44.74% 40.44% 32.03% 32.25%
Biogen Inc. 43.54% 44.99% 45.44% 40.94% 36.29%
Bristol-Myers Squibb Co. 17.39% 23.83% 11.41% 16.32% 18.90%
Eli Lilly & Co. 9.38% 16.30% 13.47% 13.56% 23.24%
Gilead Sciences Inc. 55.04% 58.87% 69.03% 62.37% 41.87%
Johnson & Johnson 24.07% 28.72% 25.05% 28.20% 25.77%
Merck & Co. Inc. 16.28% 13.51% 17.54% 13.42% 13.53%
Pfizer Inc. 25.92% 22.73% 24.20% 26.71% 29.44%
Regeneron Pharmaceuticals Inc. 35.41% 27.38% 30.51% 29.74% 36.11%
Operating Profit Margin, Sector
Pharmaceuticals & Biotechnology 23.68% 27.18% 26.43% 24.67% 23.77%
Operating Profit Margin, Industry
Health Care 16.14% 17.70% 17.41% 16.88% 16.25%

Source: Based on data from Celgene Corp. Annual Reports

2017 Calculations

1 Operating profit margin = 100 × Operating income ÷ Net product sales
= 100 × 4,707 ÷ 12,973 = 36.28%

Ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Celgene Corp.'s operating profit margin improved from 2015 to 2016 and from 2016 to 2017.

Top


Net Profit Margin

Celgene Corp., net profit margin calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Net income 2,940  1,999  1,602  2,000  1,450 
Net product sales 12,973  11,185  9,161  7,564  6,362 
Ratio
Net profit margin1 22.66% 17.87% 17.49% 26.44% 22.79%
Benchmarks
Net Profit Margin, Competitors
Abbott Laboratories 1.74% 6.71% 21.68% 11.28% 11.79%
AbbVie Inc. 18.82% 23.22% 22.50% 8.89% 21.97%
Allergan PLC -25.88% 102.76% 25.98% -12.48% -8.65%
Amgen Inc. 9.08% 35.27% 33.13% 26.69% 27.93%
Biogen Inc. 20.69% 32.34% 32.95% 30.25% 26.87%
Bristol-Myers Squibb Co. 4.85% 22.94% 9.45% 12.62% 15.64%
Eli Lilly & Co. -0.89% 12.90% 12.07% 12.19% 20.27%
Gilead Sciences Inc. 18.03% 45.07% 56.32% 49.44% 28.46%
Johnson & Johnson 1.70% 23.01% 21.99% 21.96% 19.40%
Merck & Co. Inc. 5.97% 9.85% 11.25% 28.22% 10.00%
Pfizer Inc. 40.55% 13.66% 14.25% 18.42% 42.65%
Regeneron Pharmaceuticals Inc. 20.41% 18.42% 15.50% 12.34% 20.16%
Net Profit Margin, Sector
Pharmaceuticals & Biotechnology 11.23% 24.60% 22.73% 20.93% 21.77%
Net Profit Margin, Industry
Health Care 8.69% 14.91% 14.07% 13.46% 13.91%

Source: Based on data from Celgene Corp. Annual Reports

2017 Calculations

1 Net profit margin = 100 × Net income ÷ Net product sales
= 100 × 2,940 ÷ 12,973 = 22.66%

Ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Celgene Corp.'s net profit margin improved from 2015 to 2016 and from 2016 to 2017.

Top


Return on Equity (ROE)

Celgene Corp., ROE calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Net income 2,940  1,999  1,602  2,000  1,450 
Stockholders' equity 6,921  6,599  5,919  6,525  5,590 
Ratio
ROE1 42.48% 30.29% 27.07% 30.65% 25.94%
Benchmarks
ROE, Competitors
Abbott Laboratories 1.54% 6.82% 20.85% 10.61% 10.23%
AbbVie Inc. 104.16% 128.41% 130.39% 101.84% 91.90%
Allergan PLC -5.59% 19.65% 5.11% -5.76% -7.87%
Amgen Inc. 7.84% 25.85% 24.71% 20.01% 23.00%
Biogen Inc. 20.13% 30.50% 37.84% 27.15% 21.60%
Bristol-Myers Squibb Co. 8.58% 27.55% 10.97% 13.49% 16.91%
Eli Lilly & Co. -1.76% 19.54% 16.53% 15.55% 26.57%
Gilead Sciences Inc. 22.64% 71.48% 97.70% 78.45% 27.05%
Johnson & Johnson 2.16% 23.49% 21.66% 23.40% 18.68%
Merck & Co. Inc. 6.97% 9.78% 9.94% 24.50% 8.85%
Pfizer Inc. 29.88% 12.12% 10.75% 12.81% 28.83%
Regeneron Pharmaceuticals Inc. 19.51% 20.13% 17.40% 13.69% 21.74%
ROE, Sector
Pharmaceuticals & Biotechnology 11.00% 22.76% 19.94% 20.07% 20.31%
ROE, Industry
Health Care 12.09% 20.08% 17.51% 18.41% 18.69%

Source: Based on data from Celgene Corp. Annual Reports

2017 Calculations

1 ROE = 100 × Net income ÷ Stockholders' equity
= 100 × 2,940 ÷ 6,921 = 42.48%

Ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders' equity. Celgene Corp.'s ROE improved from 2015 to 2016 and from 2016 to 2017.

Top


Return on Assets (ROA)

Celgene Corp., ROA calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Net income 2,940  1,999  1,602  2,000  1,450 
Total assets 30,141  28,086  27,053  17,340  13,378 
Ratio
ROA1 9.75% 7.12% 5.92% 11.53% 10.84%
Benchmarks
ROA, Competitors
Abbott Laboratories 0.63% 2.66% 10.72% 5.53% 6.00%
AbbVie Inc. 7.50% 9.01% 9.70% 6.44% 14.14%
Allergan PLC -3.49% 11.61% 2.88% -3.10% -3.30%
Amgen Inc. 2.48% 9.95% 9.69% 7.47% 7.68%
Biogen Inc. 10.73% 16.19% 18.19% 20.50% 15.70%
Bristol-Myers Squibb Co. 3.00% 13.22% 4.93% 5.94% 6.64%
Eli Lilly & Co. -0.45% 7.05% 6.77% 6.43% 13.29%
Gilead Sciences Inc. 6.58% 23.70% 34.93% 34.91% 13.67%
Johnson & Johnson 0.83% 11.71% 11.55% 12.45% 10.42%
Merck & Co. Inc. 2.72% 4.11% 4.36% 12.12% 4.17%
Pfizer Inc. 12.40% 4.20% 4.16% 5.40% 12.78%
Regeneron Pharmaceuticals Inc. 13.67% 12.84% 11.34% 8.99% 14.38%
ROA, Sector
Pharmaceuticals & Biotechnology 4.19% 9.23% 8.58% 9.14% 9.39%
ROA, Industry
Health Care 4.69% 8.14% 7.43% 8.24% 8.60%

Source: Based on data from Celgene Corp. Annual Reports

2017 Calculations

1 ROA = 100 × Net income ÷ Total assets
= 100 × 2,940 ÷ 30,141 = 9.75%

Ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Celgene Corp.'s ROA improved from 2015 to 2016 and from 2016 to 2017.

Top